Cargando…
Alpha-glucosidase inhibitor, acarbose, improves glycamic control and reduces body weight in type 2 diabetes: Findings on indian patients from the pooled data analysis
Alpha-glucosidase inhibitors are widely used especially in Asian countries as a treatment option for type 2 diabetes patients with high postprandial glycemia (PPG). The higher carbohydrate in the Indian diets lead to greater prandial glycemic excursion, increased glucosidase, and incretin activity i...
Autores principales: | Kalra, Sanjay, Sahay, R. K., Schnell, O., Sheu, W. H. H., Grzeszczak, W., Watada, H., Soegondo, S., Yamamoto, N., Weng, J., Rathod, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830342/ https://www.ncbi.nlm.nih.gov/pubmed/24251196 http://dx.doi.org/10.4103/2230-8210.119634 |
Ejemplares similares
-
Acarbose improves glycemic control and reduces body weight: Subanalysis data of South Asia region
por: Kalra, S, et al.
Publicado: (2013) -
Influence of gallic acid on α-amylase and α-glucosidase inhibitory properties of acarbose
por: Oboh, Ganiyu, et al.
Publicado: (2016) -
GlyCAM1 negatively regulates monocyte entry into the optic nerve head and contributes to radiation-based protection in glaucoma
por: Williams, Pete A., et al.
Publicado: (2017) -
On the potential of acarbose to reduce cardiovascular disease
por: Standl, Eberhard, et al.
Publicado: (2014) -
Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study
por: Philip, Elizabeth, et al.
Publicado: (2013)